Basic science in pulmonary hypertension

Thematic Poster
Chairs: C. Eichstaedt (Heidelberg, Germany), G. Kwapiszewska-Marsh (Graz, Austria)

Research priorities for future pulmonary hypertension research: a James Lind Alliance priority setting partnership J. Weatherald (Edmonton, Canada), H. Iqbal (St. Albert, Canada), L. Mielniczuk (Ottawa, Canada), A. Syed (Dublin, Ireland), J. Howard (Calgary, Canada), N. Dempsey (London, Canada), T. Rader (Ottawa, Canada), J. Swiston (Vancouver, Canada), S. Provencher (Québec City, Canada)
Deep learning of regulatory regions discovers enhancer variants implicated in PAH T. Tilly (Cambridge, United Kingdom), K. Auckland (Cambridge, United Kingdom), R. Nibhani (Cambridge, United Kingdom), J. Martin (Cambridge, United Kingdom), . Nihr Bioresource - Rare Diseases (Cambridge, United Kingdom), . National Cohort Study Of Idiopathic And Heritable Pah (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), P. Lio' (Cambridge, United Kingdom), S. Gräf (Cambridge, United Kingdom)
End-stage COPD patients with severe pulmonary hypertension have less airspace enlargement in histologic samples of explanted lungs K. Zeder (Graz, Austria), L. Marsh (Graz, Austria), A. Avian (Graz, Austria), L. Brcic (Graz, Austria), A. Birnhuber (Graz, Austria), P. Douschan (Graz, Austria), V. Foris (Graz, Austria), T. Sassmann (Graz, Austria), P. Böhm (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), G. Kwapiszewska (Graz, Austria), H. Olschewski (Graz, Austria), G. Kovacs (Graz, Austria)
Optical imaging outperforms micro-CT towards revealing 3D microvasculature in whole lung tissue B. Tielemans (Leuven, Belgium), F. Marain (Leuven, Belgium), F. De Bie (Leuven, Belgium), M. Coll-Llado (Barcelona, Spain), S. Munck (Leuven, Belgium), J. Deprest (Leuven, Belgium), J. Swoger (Barcelona, Spain), G. Vande Velde (Leuven, Belgium)
Correlation between right ventricular dysfunction and plasma protein profile in pulmonary hypertension A. Constantine (London, United Kingdom), C. Rhodes (London, United Kingdom), P. Ricci (London, United Kingdom), W. Li (London, United Kingdom), L. Price (London, United Kingdom), C. Mccabe (London, United Kingdom), J. Wharton (London, United Kingdom), M. Wilkins (London, United Kingdom), L. Howard (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom)
Impulse oscillometry in the assessment of patients with idiopathic arterial hypertension: a pilot study. H. Villas Bôas (Campinas, Brazil), M. Pereira (Campinas, Brazil), I. Paschoal (Campinas, Brazil)
NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function E. Mulvaney (Dublin, Ireland), F. Renzo (Dublin, Ireland), R. Adão (Porto, Portugal), G. Conceição (Porto, Portugal), E. Dupre (Sherbrooke, Canada), C. Laurent (Sherbrooke, Canada), P. Mendes-Ferreira (Porto, Portugal), C. Brás-Silva (Porto, Portugal), B. Kinsella (Dublin, Ireland)
IL-11 increases levels and activates circulating fibrocytes in different pulmonary hypertension animal models. I. Roger (Valencia, Spain), J. Milara (Valencia, Spain), P. Montero (Valencia, Spain), N. Belhadj (Valencia, Spain), J. Cortijo (Valencia, Spain)
IL-1ß may contribute to NGF-induced alterations in pulmonary hypertension C. BOUCHET (Pessac, France), G. Cardouat (Pessac, France), P. Fernandes (Pessac, France), P. Robillard (Pessac, France), R. Marthan (Pessac, France), C. Guibert (Pessac, France), V. Michel (Pessac, France)
Quantitative immunohistochemistry of PDGFRa, PDGFRß, c-KIT and CSF1R in human PAH lung samples A. Gandjeva (Aurora, CO, United States), R. Sitapara (San Diego, CA, United States), R. Tuder (Aurora, CO, United States), L. Zisman (San Diego, CA, United States)
Extended Pulmonary Retention and Tissue Distribution of Inhaled Liposomal Iloprost (L608) P. Kan (Taipei, Taiwan), K. Chen (Taipei, Taiwan)
The microbiota affects the development of the lung vascular tree in rats F. AKOUMIA (Paris, France), M. Ghigna (Paris, France), J. Cadiou (Paris, France), A. Lashermes (Paris, France), J. Riviere (Paris, France), S. Gouriou (Paris, France), R. Lagrafeuille (Brest, France), G. Hery-Arnaud (Brest, France), M. Humbert (Brest, France), N. Lapaque (Brest, France), S. Cohen-Kaminsky (Brest, France)
HS135: Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension (PH) G. Schang (Montreal, Canada), M. Poujol De Molliens (Montreal, Canada), J. Denis (Montreal, Canada), C. Chauvet (Montreal, Canada), E. Brûlé (Montreal, Canada), V. Ganesh (Montreal, Canada), J. Schoelermann (Montreal, Canada), G. Tremblay (Montreal, Canada), I. Tikhomirov (Montreal, Canada), M. O'Connor-Mccourt (Montreal, Canada)
Basement membrane regulates neointimal hyperplasia in pulmonary hypertension due to left heart disease (PH-LHD) N. Nambiar Veetil (Berlin, Germany), M. Kucherenko (Berlin, Germany), T. Gransar (Berlin, Germany), R. Szulcek (Berlin, Germany), C. Knosalla (Berlin, Germany), W. Kuebler (Berlin, Germany)
COX2 expression is downregulated in a shear stress magnitude-dependent manner in BMPR2-silenced HPAECs: implications for prostacyclin deficiency in PAH A. Mahomed (London, United Kingdom), A. Burke-Gaffney (London, United Kingdom), M. Ghazaly (London, United Kingdom), J. Naser (London, United Kingdom), Q. Toe (London, United Kingdom), G. Quinlan (London, United Kingdom), S. Wort (London, United Kingdom)
The ephrin-b2/EphB4 guidance system in pulmonary artery smooth muscle cells plays a central role in adult vascular remodeling S. Rittchen (Graz, Austria), S. Crnkovic (Graz, Austria), K. Jandl (Graz, Austria), D. Zabini (Graz, Austria), A. Mutgan (Graz, Austria), P. Boehm (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), W. Toller (Graz, Austria), C. Veith (Giessen, Germany), A. Heinemann (Graz, Austria), R. Schermuly (Giessen, Germany), A. Olschewski (Graz, Austria), L. Marsh (Graz, Austria), G. Kwapiszewska (Graz, Austria)
Pulmonary arterial changes in patients with end-stage COPD and pulmonary hypertension: computed tomography and histopathological study of the lungs. G. Martin (Strasbourg, France), M. Canuet (Strasbourg, France), A. Labani (Strasbourg, France), A. Wackenthaler (Strasbourg, France), I. Enache (Strasbourg, France), M. Chenard (Strasbourg, France), P. Dorfmüller (Giessen, Germany), D. Montani (Paris, France), R. Kessler (Strasbourg, France), M. Riou (Strasbourg, France)
Towards a GCN2 deficient model of pulmonary veno-occlusive disease M. Schwiening (CAMBRIDGE, United Kingdom), S. Moore (CAMBRIDGE, United Kingdom), A. Crosby (CAMBRIDGE, United Kingdom), M. Southwood (CAMBRIDGE, United Kingdom), C. Huang (CAMBRIDGE, United Kingdom), N. Morrell (CAMBRIDGE, United Kingdom), S. Marciniak (CAMBRIDGE, United Kingdom), E. Soon (CAMBRIDGE, United Kingdom)
Il-33 role in the pulmonary hypertension development in diabetic patients with coronary artery disease B. Shelest (Kharkiv, Ukraine), Y. Kovalova (Kharkiv, Ukraine), A. Voitovych (Kharkiv, Ukraine)